| Date | Title | Description |
| 08.11.2024 | Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference | SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the T... |
| 29.08.2024 | Mabwell's Bold Step: A New Hope for Urothelial Carcinoma | In the bustling heart of Shanghai, Mabwell is making waves. The biopharmaceutical company recently received the green light from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to kick off a Phase... |
| 26.08.2024 | Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor | SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administ... |
| 26.08.2024 | Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor | SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administ... |
| 23.08.2024 | Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer | SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administ... |
| 12.08.2024 | Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been granted Breakthrough Therapy Design... |
| 16.07.2024 | FDA Grants Orphan Drug Designation to 7MW3711 | SHANGHAI, July 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC (R&D code: 7MW3711) has been granted Orp... |
| 16.07.2024 | FDA Grants Orphan Drug Designation to 7MW3711 | SHANGHAI, July 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC (R&D code: 7MW3711) has been granted Orp... |
| 15.07.2024 | Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC | SHANGHAI, July 15, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been approved by the NMPA to enter Phase... |
| 15.07.2024 | Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC | SHANGHAI, July 15, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been approved by the NMPA to enter Phase... |
| 24.05.2024 | Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting | SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple adva... |
| 24.05.2024 | Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting | SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple adva... |
| 13.05.2024 | Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer | SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) ... |
| 13.05.2024 | Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer | SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) ... |
| 07.05.2024 | FDA Grants Orphan Drug Designation to 9MW2821 | SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Or... |
| 07.05.2024 | FDA Grants Orphan Drug Designation to 9MW2821 | SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Or... |
| 25.04.2024 | 2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor | SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for... |
| 16.04.2024 | Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting | SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format a... |
| 08.04.2024 | MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China | SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its whol... |
| 21.03.2024 | Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London | SHANGHAI, March 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, published "Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index a... |
| 19.03.2024 | SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential | SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary o... |
| 12.03.2024 | Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting | SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR ... |
| 11.03.2024 | Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London | SHANGHAI, March 11, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present its next generation ADC platform IDDC™ and the latest study results of m... |
| 08.03.2024 | Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer | SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin... |
| 27.02.2024 | FDA Grants Fast Track Designation to 9MW2821 | SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fa... |
| 21.02.2024 | Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology | SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top ... |
| 20.02.2024 | FDA Grants Orphan Drug Designation to 9MW3011 | SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-... |
| 20.02.2024 | Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711 | SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malig... |
| 02.01.2024 | Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase | SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that Dr. Hai Wu, President of R&D of Mabwell, will attend 42nd JP Morgan Healthcare Conference and... |
| 25.10.2023 | Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO | Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reporte... |
| 23.10.2023 | Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs | SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical... |
| 28.09.2023 | Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor | SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D cod... |
| 22.09.2023 | FDA Grants Fast Track Designation to 9MW3011 | SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-... |
| 08.09.2023 | Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics | SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic colla... |
| 26.07.2023 | Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023 | SHANGHAI, July 26, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9M... |
| 22.07.2023 | Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND | SHANGHAI, July 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the... |
| 19.07.2023 | Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND | SHANGHAI, July 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National ... |
| 15.06.2023 | Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal | SHANGHAI, June 15, 2023 /PRNewswire/ -- Recently, the preclinical study results of 9MW2821, the first domestically developed Nectin-4-targeting ADC by Mabwell, were published in the renowned journal "Molecular Cancer Therapeutics"... |
| 15.06.2023 | Mabwell Announces the U.S. FDA approval of 9MW3811 for IND | SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the entire value chain of the pharmaceutical industry, announced the clinical trial application of its self-developed 9MW3811 injectio... |
| 07.04.2023 | China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released | SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promisin... |
| 07.04.2023 | China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released | SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promisin... |
| 03.04.2023 | The World's Second Approved Biosimilars of Denosumab (MAILISHU) | SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311),... |
| 14.03.2023 | Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011 | SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW... |
| 28.02.2023 | First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND | SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary... |
| 20.01.2023 | $412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases | SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DIS... |
| 20.12.2022 | Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries | SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the... |
| 24.11.2022 | Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND | SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycyth... |